Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2019 and provide an update on operations and FDA regulatory status after the market closes on Wednesday, May 8, 2019.
In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and current business developments.
Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 7475517.
A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company’s website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website for 90 days.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia. Premarket approval for the r-SNM System is currently pending with the U.S. Food & Drug Administration. For more information, visit the Companys website at www.axonicsmodulation.com.
Axonics Modulation Technologies, Inc.
President & Chief Financial Officer
& Media Contact
Matt Clawson, +1-949-370-8500